Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syncom Formulation (India)BOM:524470 +0.92%86 Days Inventory is 68.87 as of Mar. 2026, which is 74% above its 10-year median of 39.63. GuruFocus rates BOM:524470 with a GF Score™ of 86/100 and a GF Value™ of ₹20.18 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 923 Drug Manufacturers companies, Syncom Formulation (India) ranks better than 92.63% on this metric.
The historical rank and industry rank for Syncom Formulation (India)'s Days Inventory or its related term are showing as below:
BOM:524470'
s Days Inventory Range Over the Past 10 Years
Min: 32.03 Med: 39.63 Max: 66.9
Current: 56.81
During the past 13 years, Syncom Formulation (India)'s highest Days Inventory was 66.90. The lowest was 32.03. And the median was 39.63.
BOM:524470's Days Inventory is ranked better than 92.63% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs BOM:524470: 56.81
Inventory Turnover measures how fast the company turns over its inventory within a year.
Syncom Formulation (India)'s Inventory Turnover for the
three
months ended in Mar. 2026 was 1.32.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Syncom Formulation (India)'s Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.46.
Syncom Formulation (India) (BOM:524470) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Syncom Formulation (India)'s Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Syncom Formulation (India)'s Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Syncom Formulation (India) Days Inventory Related Terms
Syncom Formulation (India) Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India) Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Days Inventory distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syncom Formulation (India) (BOM:524470) has a Days Inventory of 68.87 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Syncom Formulation (India) and its competitors. This is 74% above median its historical median of 39.63. Over the past decade, Syncom Formulation (India)'s Days Inventory has ranged from 32.03 to 66.90. According to the industry distribution chart, Syncom Formulation (India) ranks #68 out of 923 companies in the Drug Manufacturers industry, placing it in the top 7.4%.
Is Syncom Formulation (India)'s Days Inventory too high?
Syncom Formulation (India)'s current Days Inventory of 68.87 is 74% above median its 10-year median of 39.63. Over the past 10 years, this metric has ranged from a low of 32.03 to a high of 66.90. The Drug Manufacturers industry median Days Inventory is 164.87. Syncom Formulation (India)'s value of 68.87 is 58.2% below this industry median. Based on the distribution chart, Syncom Formulation (India) ranks #68 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Syncom Formulation (India) has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #68 out of 923 companies for Days Inventory. This places Syncom Formulation (India) in the top 7% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.87. Syncom Formulation (India)'s value of 68.87 is 58.2% below this benchmark. Historically, Syncom Formulation (India)'s own Days Inventory has ranged from 32.03 to 66.90 over the past decade. While the company's 10-year median is 39.63 vs. the industry median of 164.87, Syncom Formulation (India) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syncom Formulation (India)'s current Days Inventory of 68.87 is 58.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Syncom Formulation (India) and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current Days Inventory is 68.87, which is 74% above median its own 10-year median of 39.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹20.18, compared to a current price of ₹13.15 — trading 34.8% below its estimated fair value. The current Days Inventory is 68.87, which is 74% above median its 10-year median of 39.63 and 58.2% below the Drug Manufacturers industry median of 164.87. Syncom Formulation (India)'s overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current Days Inventory is 68.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?
Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued.
The current stock price of ₹13.15 is trading 34.8% below its estimated GF Value™ of ₹20.18.
GuruFocus considers Syncom Formulation (India) to be Significantly Undervalued.
Key valuation signals for BOM:524470:
Days Inventory: 68.87 (74% above median its 10-year median of 39.63)
GF Value™: ₹20.18 vs. price of ₹13.15 (34.8% below fair value)
Industry Position: 58.2% below the Drug Manufacturers median (#68 of 923)
No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
86GF Score
Get the complete analysis for BOM:524470
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524470 has been successfully added to your 
